Maze Therapeutics (MAZE) Operating Leases (2024 - 2026)

Maze Therapeutics (MAZE) has 3 years of Operating Leases data on file, last reported at $17.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 17.01% year-over-year to $17.6 million; the trailing twelve-month figure through Mar 2026 stood at $17.6 million (down 17.01% YoY), and the FY2025 full-year result was $18.5 million, down 15.84% from the prior year.
• Operating Leases eased to $17.6 million in Q1 2026, from $18.5 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $22.0 million in Q4 2024 to a low of $17.6 million in Q1 2026.
• A 3-year average of $19.8 million and a median of $19.9 million in 2025 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases decreased 15.84% in 2025 and retreated 17.01% in 2026, its largest moves.
• Tracing MAZE's Operating Leases over 3 years: stood at $22.0 million in 2024, then declined by 15.84% to $18.5 million in 2025, then dropped by 5.18% to $17.6 million in 2026.
• Business Quant data shows MAZE's Operating Leases at $17.6 million in Q1 2026, $18.5 million in Q4 2025, and $19.4 million in Q3 2025.